CTLT - Catalent Inc Stock Price, Fair Value and News

$63.48

Market Closed as of 17 Dec 2024, 04:00 pm ET

CTLT Stock Valuation Analysis

Valuation

Max Portfolio %

CTLT Price Action

CTLT RSI Chart

CTLT Stock Valuation Analysis

Valuation

Max Portfolio %

CTLT Valuation

CTLT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CTLT Fundamentals

CTLT Revenue

CTLT Earnings

CTLT Profitability

CTLT Investor Care

Revenue & Growth

How Catalent Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

Net sales

Year	Q1	Q2	Q3	Q4
2024	4.1B	4.4B	4.4B	-
2023	4.5B	4.3B	4.2B	4.1B
2022	4.7B	4.8B	4.8B	4.7B
2021	5.9B	4.0B	4.2B	4.5B
2020	2.9B	5.2B	5.4B	5.6B
2019	2.5B	2.5B	2.6B	2.7B
2018	2.4B	2.5B	2.5B	2.5B
2017	2.0B	2.1B	2.2B	2.3B
2016	1.8B	1.8B	1.9B	1.9B
2015	1.8B	1.8B	1.8B	1.8B
2014	1.8B	1.8B	1.8B	1.8B
2013	1.8B	1.8B	1.8B	1.8B
2012	-	1.7B	1.7B	1.7B

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Catalent Inc

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics, and cell and gene therapies in clinical trials. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply services. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey.

CEO	Mr. Alessandro Maselli
WEBSITE	catalent.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers Specialty & Generic
EMPLOYEES	17800